These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 36016267)

  • 1. Vaccination, Risk Factors and Outcomes of COVID-19 Infection in Patients with Psoriasis-A Single Centre Real-Life Experience from Eastern Slovakia.
    Baloghová J; Kampe T; Kolarčik P; Hatalová E
    Viruses; 2022 Jul; 14(8):. PubMed ID: 36016267
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence, outcomes and associated factors of SARS-CoV-2 infection in psoriasis patients of Southwest China: a cross-sectional survey.
    Zou Y; Xu J; Chen AJ; Huang K; Zhu SM; Li JJ; He J; Li JZ; Xiong JX; Fan YK; Liu C; Pan Y; Wang P
    Sci Rep; 2024 Mar; 14(1):6331. PubMed ID: 38491005
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [BIOLOGICAL TREATMENT OF PSORIASIS IN TIME OF NEW CORONAVIRUS INFECTION COVID-19].
    Kruglova LS; Pereverzina NO; Rudneva NS; Kamynina NN; Oynotkinova OS
    Probl Sotsialnoi Gig Zdravookhranenniiai Istor Med; 2021 Aug; 29(Special Issue):1381-1387. PubMed ID: 34792893
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Coronavirus disease 2019 vaccination in patients with psoriasis: A position statement from India by SIG psoriasis (IADVL Academy).
    Parthasaradhi A; Ganguly S; Kar BR; Thomas J; Neema S; Tahiliani S; Sathishkumar D; Parasramani SG; Chalam KV; Komeravalli H
    Indian J Dermatol Venereol Leprol; 2022; 88(3):286-290. PubMed ID: 35434988
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence, risk and severity of SARS-CoV-2 infections in psoriasis patients receiving conventional systemic, biologic or topical treatment during the COVID-19 pandemic: a cross-sectional cohort study (PsoCOVID).
    Kwee KV; Murk JL; Yin Q; Visch MB; Davidson L; de Jong EMGJ; van den Reek JMPA; Tjioe M
    J Dermatolog Treat; 2023 Dec; 34(1):2161297. PubMed ID: 36545844
    [TBL] [Abstract][Full Text] [Related]  

  • 7. COVID-19 Cases and Hospitalizations by COVID-19 Vaccination Status and Previous COVID-19 Diagnosis - California and New York, May-November 2021.
    León TM; Dorabawila V; Nelson L; Lutterloh E; Bauer UE; Backenson B; Bassett MT; Henry H; Bregman B; Midgley CM; Myers JF; Plumb ID; Reese HE; Zhao R; Briggs-Hagen M; Hoefer D; Watt JP; Silk BJ; Jain S; Rosenberg ES
    MMWR Morb Mortal Wkly Rep; 2022 Jan; 71(4):125-131. PubMed ID: 35085222
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SARS-CoV-2 vaccine uptake in a multi-ethnic UK healthcare workforce: A cross-sectional study.
    Martin CA; Marshall C; Patel P; Goss C; Jenkins DR; Ellwood C; Barton L; Price A; Brunskill NJ; Khunti K; Pareek M
    PLoS Med; 2021 Nov; 18(11):e1003823. PubMed ID: 34739480
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acceptance of COVID-19 vaccination and influencing factors among people living with HIV in Guangxi, China: a cross-sectional survey.
    Su J; Jia Z; Wang X; Qin F; Chen R; Wu Y; Lu B; Lan C; Qin T; Liao Y; Shi M; Liao Y; Pan P; Ye L; Jiang J; Liang H
    BMC Infect Dis; 2022 May; 22(1):471. PubMed ID: 35578187
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Attitudes towards vaccines and intention to vaccinate against COVID-19: a cross-sectional analysis-implications for public health communications in Australia.
    Enticott J; Gill JS; Bacon SL; Lavoie KL; Epstein DS; Dawadi S; Teede HJ; Boyle J;
    BMJ Open; 2022 Jan; 12(1):e057127. PubMed ID: 34980631
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Investigation of Humoral and Cellular Immunity in TOBB ETÜ Hospital Workers After Three Doses of CoronaVac Vaccination and after One Dose of Comirnaty Vaccination Following Two Doses of CoronaVac].
    Özyurda F; Ardıçoğlu Akışın Y; Mert T; Poyraz B; Özkan Y; Turan M; Göçmen JS; Yücel A; Akar N
    Mikrobiyol Bul; 2022 Jul; 56(3):387-403. PubMed ID: 35960233
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the dose-effect association between the number of doses and duration since the last dose of COVID-19 vaccine, and its efficacy in preventing the disease and reducing disease severity: A single centre, cross-sectional analytical study from India.
    Bhattacharya A; Ranjan P; Ghosh T; Agarwal H; Seth S; Maher GT; Upadhyay AD; Kumar A; Baitha U; Gupta G; Prakash B; Dwivedi SN; Wig N
    Diabetes Metab Syndr; 2021; 15(5):102238. PubMed ID: 34364299
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety of COVID-19 vaccines in patients with psoriasis undergoing therapy with anti-interleukin agents.
    Talamonti M; Galluzzo M
    Expert Opin Biol Ther; 2021 Nov; 21(11):1535-1537. PubMed ID: 34357839
    [No Abstract]   [Full Text] [Related]  

  • 14. The prevalence of SARS-CoV-2 infection and the severity of the course of COVID-19 in patients with psoriasis treated with biologic therapy.
    Ciechanowicz P; Dopytalska K; Mikucka-Wituszyńska A; Dźwigała M; Wiszniewski K; Herniczek W; Szymańska E; Walecka I
    J Dermatolog Treat; 2022 May; 33(3):1581-1584. PubMed ID: 33317364
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers.
    Lustig Y; Sapir E; Regev-Yochay G; Cohen C; Fluss R; Olmer L; Indenbaum V; Mandelboim M; Doolman R; Amit S; Mendelson E; Ziv A; Huppert A; Rubin C; Freedman L; Kreiss Y
    Lancet Respir Med; 2021 Sep; 9(9):999-1009. PubMed ID: 34224675
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adverse events and breakthrough infections associated with COVID-19 vaccination in the Indian population.
    Arora G; Taneja J; Bhardwaj P; Goyal S; Naidu K; Yadav SK; Saluja D; Jetly S
    J Med Virol; 2022 Jul; 94(7):3147-3154. PubMed ID: 35261064
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of SARS-CoV-2 Virus Infection on the Course of Psoriasis during Treatment with Biological Drugs.
    Mroz M; Mućka S; Miodońska M; Ziolkowska D; Hadas E; Bożek A
    Medicina (Kaunas); 2021 Aug; 57(9):. PubMed ID: 34577804
    [No Abstract]   [Full Text] [Related]  

  • 18. Association of BNT162b2 Vaccine Third Dose Receipt With Incidence of SARS-CoV-2 Infection, COVID-19-Related Hospitalization, and Death Among Residents of Long-term Care Facilities, August to October 2021.
    Muhsen K; Maimon N; Mizrahi AY; Varticovschi B; Bodenheimer O; Cohen D; Dagan R
    JAMA Netw Open; 2022 Jul; 5(7):e2219940. PubMed ID: 35796153
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decreasing neutralization antibody levels following vaccination against SARS-CoV-2 in the elderly: an observational study in Southern Moravia, Czech Republic.
    Mravčík V; Husa P; Kumpanová Valachovičová S; Vobořil J
    Epidemiol Mikrobiol Imunol; 2022; 71(1):9-20. PubMed ID: 35477266
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association Between Vaccination With BNT162b2 and Incidence of Symptomatic and Asymptomatic SARS-CoV-2 Infections Among Health Care Workers.
    Angel Y; Spitzer A; Henig O; Saiag E; Sprecher E; Padova H; Ben-Ami R
    JAMA; 2021 Jun; 325(24):2457-2465. PubMed ID: 33956048
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.